Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

Matchpoint Therapeutics is preparing to take its oral T cell modulator through proof-of-concept clinical testing in ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...

Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...

Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

The Nobel Prize in Chemistry 2026 has been awarded to two scientists - Henri B Kagan and Kensō Soai – for discoveries on ...

Pfizer acquired Tukysa as part of its $43 billion takeover of Seagen in 2023, three years after the drug first reached the US ...

Just months after launching an open-source 'virtual biology' platform, non-profit research organisation Biohub has raised ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...